Cargando…

Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk

BACKGROUND: Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinrich, Michael, Scotti, Francesca, Andrade-Cetto, Adolfo, Berger-Gonzalez, Monica, Echeverría, Javier, Friso, Fabio, Garcia-Cardona, Felipe, Hesketh, Alan, Hitziger, Martin, Maake, Caroline, Politi, Matteo, Spadafora, Carmenza, Spadafora, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294742/
https://www.ncbi.nlm.nih.gov/pubmed/32581783
http://dx.doi.org/10.3389/fphar.2020.00765
_version_ 1783546536040333312
author Heinrich, Michael
Scotti, Francesca
Andrade-Cetto, Adolfo
Berger-Gonzalez, Monica
Echeverría, Javier
Friso, Fabio
Garcia-Cardona, Felipe
Hesketh, Alan
Hitziger, Martin
Maake, Caroline
Politi, Matteo
Spadafora, Carmenza
Spadafora, Rita
author_facet Heinrich, Michael
Scotti, Francesca
Andrade-Cetto, Adolfo
Berger-Gonzalez, Monica
Echeverría, Javier
Friso, Fabio
Garcia-Cardona, Felipe
Hesketh, Alan
Hitziger, Martin
Maake, Caroline
Politi, Matteo
Spadafora, Carmenza
Spadafora, Rita
author_sort Heinrich, Michael
collection PubMed
description BACKGROUND: Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of “the fair and equitable sharing of benefits arising from the utilization of genetic resources” (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges. AIMS: Using a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries—Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research. RESULTS AND DISCUSSIONS: The implementation of the NP varies in the six countries; and while they are all rich in biodiversity, access and benefit sharing mechanisms differ considerably. There is a need to engage in a consultation process with stakeholders, but this has often come to a halt. Institutional infrastructures to implement national policies are weak, and the level of knowledge about the NP and the CBD within countries remains limited. CONCLUSIONS: Different policies in the six countries result in very diverse strategies and opportunities relating to the equitable use of biodiversity. A long-term strategy is required to facilitate a better understanding of the treaties and the resulting opportunities for a fairer development and implementation of transparent national polices, which currently differ in the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled for all stakeholders involved including local communities.
format Online
Article
Text
id pubmed-7294742
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72947422020-06-23 Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk Heinrich, Michael Scotti, Francesca Andrade-Cetto, Adolfo Berger-Gonzalez, Monica Echeverría, Javier Friso, Fabio Garcia-Cardona, Felipe Hesketh, Alan Hitziger, Martin Maake, Caroline Politi, Matteo Spadafora, Carmenza Spadafora, Rita Front Pharmacol Pharmacology BACKGROUND: Global challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of “the fair and equitable sharing of benefits arising from the utilization of genetic resources” (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges. AIMS: Using a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries—Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research. RESULTS AND DISCUSSIONS: The implementation of the NP varies in the six countries; and while they are all rich in biodiversity, access and benefit sharing mechanisms differ considerably. There is a need to engage in a consultation process with stakeholders, but this has often come to a halt. Institutional infrastructures to implement national policies are weak, and the level of knowledge about the NP and the CBD within countries remains limited. CONCLUSIONS: Different policies in the six countries result in very diverse strategies and opportunities relating to the equitable use of biodiversity. A long-term strategy is required to facilitate a better understanding of the treaties and the resulting opportunities for a fairer development and implementation of transparent national polices, which currently differ in the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled for all stakeholders involved including local communities. Frontiers Media S.A. 2020-06-08 /pmc/articles/PMC7294742/ /pubmed/32581783 http://dx.doi.org/10.3389/fphar.2020.00765 Text en Copyright © 2020 Heinrich, Scotti, Andrade-Cetto, Berger-Gonzalez, Echeverría, Friso, Garcia-Cardona, Hesketh, Hitziger, Maake, Politi, Spadafora and Spadafora http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Heinrich, Michael
Scotti, Francesca
Andrade-Cetto, Adolfo
Berger-Gonzalez, Monica
Echeverría, Javier
Friso, Fabio
Garcia-Cardona, Felipe
Hesketh, Alan
Hitziger, Martin
Maake, Caroline
Politi, Matteo
Spadafora, Carmenza
Spadafora, Rita
Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title_full Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title_fullStr Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title_full_unstemmed Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title_short Access and Benefit Sharing Under the Nagoya Protocol—Quo Vadis? Six Latin American Case Studies Assessing Opportunities and Risk
title_sort access and benefit sharing under the nagoya protocol—quo vadis? six latin american case studies assessing opportunities and risk
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294742/
https://www.ncbi.nlm.nih.gov/pubmed/32581783
http://dx.doi.org/10.3389/fphar.2020.00765
work_keys_str_mv AT heinrichmichael accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT scottifrancesca accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT andradecettoadolfo accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT bergergonzalezmonica accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT echeverriajavier accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT frisofabio accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT garciacardonafelipe accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT heskethalan accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT hitzigermartin accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT maakecaroline accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT politimatteo accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT spadaforacarmenza accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk
AT spadaforarita accessandbenefitsharingunderthenagoyaprotocolquovadissixlatinamericancasestudiesassessingopportunitiesandrisk